BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34670872)

  • 21. Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma.
    Lei P; Yu L; Sun X; Hao J; Shi W; Sun H; Guo X; Jia X; Liu T; Zhang DL; Li L; Wang H; Xu C
    Med Oncol; 2024 Jan; 41(2):48. PubMed ID: 38177789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
    Lu X; Jing L; Liu S; Wang H; Chen B
    Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.
    Wu J; Zhou X; Ren J; Zhang Z; Ju H; Diao X; Jiang S; Zhang J
    Comput Biol Med; 2023 Sep; 163():107164. PubMed ID: 37329616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
    Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
    Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The construction, validation and promotion of the nomogram prognosis prediction model of UCEC, and the experimental verification of the expression and knockdown of the key gene GPX4.
    Zhang L; Wang J; Guo Y; Yue H; Zhang M
    Heliyon; 2024 Jan; 10(2):e24415. PubMed ID: 38312660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human
    Rathbun LA; Magliocco AM; Bamezai AK
    Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
    Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
    Front Oncol; 2021; 11():766947. PubMed ID: 34868993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-binding protein with serine-rich domain 1 regulates microsatellite instability of uterine corpus endometrial adenocarcinoma.
    Liu X; Ma H; Ma L; Li K; Kang Y
    Clinics (Sao Paulo); 2021; 76():e3318. PubMed ID: 34817046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
    Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
    Li J; Xu W; Zhu Y
    Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.
    Miao L; Chen B; Jing L; Zeng T; Chen Y
    Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38305309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
    Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
    Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin.
    Li Y; Yu S; Li Y; Liang X; Su M; Li R
    Front Endocrinol (Lausanne); 2021; 12():714909. PubMed ID: 34712201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis.
    Engevik KA; Engevik MA; Engevik AC
    PLoS One; 2023; 18(1):e0280428. PubMed ID: 36662766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
    Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
    World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.
    Zheng X; Lv X; Zhu L; Xu K; Shi C; Cui L; Ding H
    Cancer Manag Res; 2021; 13():9329-9343. PubMed ID: 34992456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.